email article
Treatment with tofacitinib (Xeljanz) proved to be rapidly effective for moderate-to-severe ulcerative colitis (UC), even in patients who previously failed tumor necrosis factor (TNF) inhibition, post hoc analysis of trial data indicated.
While the oral small-molecule JAK inhibitor had greater efficacy than placebo for both induction and maintenance of remission, rates of herpes zoster (serious and non-serious) were numerically higher in tofacitinib recipients, regardless of previous response to TNF inhibition, reported William Sandborn, MD, of the University of California San Diego.
TNF inhibitor failure has been suggested as a predictor of poor prognosis in UC. Patients refractory to this therapy may be more challenging to treat, and therefore have an unmet need for alternative therapies.
Prometheus Biosciences Announces Appointment of Mark Stenhouse as Chief Operating Officer
News provided by
Share this article
Share this article
SAN DIEGO, March 4, 2021 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointment of commercial veteran Mark Stenhouse as Chief Operating Officer. Mark s leadership and deep experience with GI diagnostics and therapeutics make him a great fit for Chief Operating Officer, which is a key role as we accelerate our growth, said Mark McKenna, President and CEO of Prometheus. His thirty years of biopharma industry experience, and building and leading successful teams, will strengthen our leadership team as we seek to revolutionize the treatment of IBD with a precision medicine a
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery System for GI Diseases - read this article along with other careers information, tips and advice on BioSpace
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Progenity Initiates Safety and Tolerability Study of its Smart Capsule-Based Oral Drug Delivery .
Progenity, Inc.February 17, 2021 GMT
SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success developing and commercializing molecular testing products, today announced the initiation of a clinical study for their Drug Delivery System (DDS) capsule, an ingestible and self-guided drug delivery device. The study will evaluate the capsule’s safety and tolerability in the gastrointestinal (GI) tract of Normal Healthy Volunteers (NHV). The study will also collect the first clinical data on the ability of the DDS to auto-locate and accurately deliver a payload to the colon, a key delivery site for the treatment of ulcerative colitis.
Share this article
Share this article
SAN DIEGO, Feb. 16, 2021 /PRNewswire/ Prometheus Biosciences, Inc. ( Prometheus ), a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of inflammatory bowel disease (IBD), today announced the appointments of Judith L. Swain, MD and Helen C. Adams to its board of directors. Ms. Adams will assume the position of Chair of the Audit Committee. We re thrilled to have Judith and Helen join our Board of Directors, who bring significant clinical medicine and financial expertise that will be important as we advance our pipeline to people living with IBD, said Mark McKenna, President and CEO of Prometheus. Judith is a distinguished physician scientist and veteran scientific advisory board member with an international perspective on drug development. Helen is an outstanding financial professional and exper